title: Novel effect of cyclicization of the Arg-Gly-Asp-containing peptide on vitronectin binding to platelets.
abstract: Vitronectin is one of the glycoproteins that mediate cell adhesion and spreading of a variety of cells through the RGD(S) sequence. Vitronectin is demonstrated to bind to glycoprotein IIb-IIIa and play a role in platelet aggregation. Synthetic peptides containing the RGD(S) sequence can inhibit vitronectin binding to platelets, but the affinity of these peptides is less than 1/100th that of native vitronectin. The present study thus examined the ability of modified RGD(S)-containing peptide to inhibit vitronectin binding to thrombin-stimulated platelets. The cyclicization of GRGDSPA peptide was done by the linkage of NH2-terminal glycin and the COOH-terminal alanin. The circular dichroism spectrum of cyclic GRGDSPA peptide only showed negative minimum at approximately 220 nm, but those of other linear peptides such as GRGDSPA and GRGESPA had no effect. This result indicated that only the cyclic GRGDSPA peptide retained some conformational structure to restrict its flexibility. Inhibition experiments revealed that the affinities of the ligands for the receptor decreased in the order of vitronectin = fibronectin = fibrinogen = von Willebrand factor (vWF) greater than cyclic GRGDSPA peptide greater than GRGDSPA peptide. GRGESPA peptide had no effect. These results demonstrate that the conformational structure of the RGD(S) sequence plays the important role for the affinity of vitronectin binding to activated platelets and the increased affinity of the modified peptide is a prerequisite for the potential antithrombotic use.
authors.affiliation: First Department of Internal Medicine, School of Medicine, Yokohama City University, Japan.
authors.forename: H
authors.initials: H
authors.lastname: Mohri
authors.forename: Y
authors.initials: Y
authors.lastname: Hashimoto
authors.forename: M
authors.initials: M
authors.lastname: Ohba
authors.forename: H
authors.initials: H
authors.lastname: Kumagai
authors.forename: T
authors.initials: T
authors.lastname: Ohkubo
mesh_terms: D000595:Amino Acid Sequence; D001792:Blood Platelets / Q000187:drug effects / Q000378:metabolism*; D002942:Circular Dichroism; D004305:Dose-Response Relationship, Drug; D005340:Fibrinogen / Q000494:pharmacology; D005353:Fibronectins / Q000494:pharmacology; D006023:Glycoproteins / Q000378:metabolism*; D006801:Humans; D007457:Iodine Radioisotopes; D008968:Molecular Conformation; D008969:Molecular Sequence Data; D009842:Oligopeptides / Q000032:analysis*; D010456:Peptides, Cyclic / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology*; D013917:Thrombin / Q000494:pharmacology; D019096:Vitronectin; D014841:von Willebrand Factor / Q000494:pharmacology
chemical_list: D005353:Fibronectins; D006023:Glycoproteins; D007457:Iodine Radioisotopes; D009842:Oligopeptides; D010456:Peptides, Cyclic; D019096:Vitronectin; D014841:von Willebrand Factor; C068733:cyclo(glycyl-arginyl-glycyl-aspartyl-seryl-aspartyl-alanyl); C047981:arginyl-glycyl-aspartic acid; D005340:Fibrinogen; D013917:Thrombin